LQDA Stock Price, Liquidia Corporation Quote, Chart

Market Summary

USD12.69-0.05

Delayed

-0.39%

LQDA Alerts

1 major insider sales recently.

LQDA Stock Price

View Fullscreen

LQDA RSI Chart

LQDA Valuation

Market Cap

969.3M

Price/Earnings (Trailing)

-9.01

Price/Sales (Trailing)

60.71

Price/Free Cashflow

-16.28

LQDA Price/Sales (Trailing)

LQDA Profitability

Return on Equity

-124.78%

Return on Assets

-54.6%

Free Cashflow Yield

-6.14%

LQDA Fundamentals

LQDA Revenue

Revenue (TTM)

16.0M

Rev. Growth (Yr)

-33.85%

Rev. Growth (Qtr)

-34.41%

LQDA Earnings

Earnings (TTM)

-107.6M

Earnings Growth (Yr)

-248.23%

Earnings Growth (Qtr)

-49.13%

Breaking Down LQDA Revenue

Last 7 days

5.2%

Last 30 days

-8.4%

Last 90 days

-13.0%

Trailing 12 Months

62.3%

How does LQDA drawdown profile look like?

LQDA Financial Health

Current Ratio

7.66

Debt/Equity

0.23

Debt/Cashflow

-2.92

LQDA Investor Care

Shares Dilution (1Y)

18.02%

Diluted EPS (TTM)

-1.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	16.0M	0	0	0
2023	16.9M	17.8M	18.3M	17.5M
2022	13.3M	13.8M	13.8M	15.9M
2021	3.8M	6.8M	9.8M	12.9M
2020	0	0	0	739.6K
2019	0	0	0	8.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Liquidia Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	saggar rajeev	sold	-22,558	13.68	-1,649	chief medical officer
Apr 12, 2024	moomaw scott	sold	-23,109	14.58	-1,585	chief commercial officer
Apr 12, 2024	saggar rajeev	sold	-22,234	14.58	-1,525	chief medical officer
Apr 12, 2024	adair jason	sold	-17,335	14.58	-1,189	chief business officer
Apr 12, 2024	schundler russell	sold	-30,034	14.58	-2,060	general counsel
Apr 12, 2024	kaseta michael	sold	-45,722	14.58	-3,136	cfo and coo
Apr 12, 2024	jeffs roger	sold	-121,889	14.58	-8,360	chief executive officer
Apr 11, 2024	adair jason	acquired	-	-	3,906	chief business officer
Mar 18, 2024	kaseta michael	sold	-192,466	15.82	-12,166	cfo and coo
Mar 18, 2024	jeffs roger	sold	-452,183	15.82	-28,583	chief executive officer

Which funds bought or sold LQDA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	new	-	1,283	1,283	-%
May 16, 2024	SkyView Investment Advisors, LLC	reduced	-16.42	33,000	1,375,000	0.25%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	491	587,192	681,170	-%
May 16, 2024	JANE STREET GROUP, LLC	added	892	4,155,480	4,527,390	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-78.13	-4,821,520	1,766,760	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-38.83	-1,300,440	3,900,800	-%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	new	-	271,828	271,828	-%
May 15, 2024	Royal Bank of Canada	reduced	-83.53	-155,000	39,000	-%
May 15, 2024	FARALLON CAPITAL MANAGEMENT LLC	new	-	30,311,200	30,311,200	0.14%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	new	-	2,212,500	2,212,500	0.23%

Are Funds Buying or Selling LQDA?

Are funds buying LQDA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LQDA

No. of Funds

LQDA Alerts

1 major insider sales recently.

Unveiling Liquidia Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	manning paul b	9.2%	6,328,721	SC 13G/A
Feb 07, 2024	blackrock inc.	4.97%	3,411,840	SC 13G/A
Jan 31, 2024	blackrock inc.	5.2%	3,529,461	SC 13G
Jan 16, 2024	legend aggregator, lp	9.5%	7,182,532	SC 13G
Dec 14, 2023	caligan partners lp	15.1%	10,360,945	SC 13D/A
May 05, 2023	blackrock inc.	4.99%	3,232,051	SC 13G
Feb 14, 2023	manning paul b	9.3%	6,024,113	SC 13G/A
Feb 13, 2023	blackrock inc.	5.1%	3,282,762	SC 13G
Feb 01, 2023	canaan viii lp	4.5%	2,917,169	SC 13G/A
Feb 14, 2022	manning paul b	10.0%	5,175,172	SC 13G/A

Recent SEC filings of Liquidia Corporation

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 23, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading

Peers (Alternatives to Liquidia Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Liquidia Corporation News

Latest updates

Liquidia Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Revenue	-34.4%	2,972	4,531	3,678	4,786	4,493	5,360	3,165	3,918	3,492	3,215	3,179	3,376	3,084	-	-
Costs and Expenses	2.6%	31,773	30,967	18,569	27,611	13,725	11,857	11,996	12,888	17,964	14,577	10,259	9,730	12,085	16,653	-
S&GA Expenses	-100.0%	-	17,145	10,559	9,245	7,793	6,187	6,744	6,938	12,542	8,470	4,882	4,421	5,337	11,167	-
R&D Expenses	-21.6%	10,057	12,829	7,440	17,695	5,278	4,976	4,512	5,219	4,728	5,381	4,487	4,595	6,054	5,248	-
Interest Expenses	28.6%	2,524	1,962	1,761	1,426	1,124	698	620	542	478	204	205	203	150	201	-
Net Income	-49.1%	-40,900	-27,426	-15,790	-23,517	-11,745	-6,533	-9,092	-9,447	-15,943	-11,563	-7,281	-6,552	-9,183	-16,086	-
Net Income Margin	-50.2%	-6.74*	-4.49*	-3.14*	-2.86*	-2.17*	-2.57*	-3.34*	-3.20*	-3.12*	-2.69*	-3.98*	-6.88*	-	-	-
Free Cashflow	-57.5%	-25,490	-16,188	-12,036	-5,807	-8,823	-5,094	-5,868	-8,436	-9,782	-7,579	-5,831	-8,294	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	66.6%	197	118	112	122	129	129	133	139	94.00	94.00	100	104	88.00	100	69.00
Current Assets	86.8%	168	90.00	83.00	93.00	100	100	103	109	62.00	61.00	67.00	71.00	55.00	66.00	56.00
Cash Equivalents	88.6%	158	84.00	76.00	88.00	94.00	93.00	98.00	104	58.00	57.00	64.00	68.00	54.00	65.00	56.00
Net PPE	24.5%	6.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	6.00	6.00	7.00	9.00
Goodwill	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	-
Liabilities	56.0%	111	71.00	64.00	61.00	47.00	39.00	38.00	37.00	38.00	28.00	27.00	25.00	26.00	28.00	34.00
Current Liabilities	18.2%	22.00	19.00	12.00	19.00	7.00	9.00	7.00	7.00	8.00	7.00	7.00	7.00	8.00	12.00	17.00
Long Term Debt	-	-	-	-	-	-	20.00	20.00	20.00	19.00	19.00	10.00	10.00	10.00	10.00	10.00
LT Debt, Non Current	-	-	-	-	-	-	20.00	20.00	20.00	19.00	19.00	10.00	10.00	10.00	10.00	10.00
Shareholder's Equity	82.4%	86.00	47.00	48.00	61.00	82.00	90.00	95.00	102	55.00	65.00	73.00	79.00	63.00	71.00	35.00
Retained Earnings	-9.5%	-470	-429	-401	-385	-362	-350	-344	-334	-325	-309	-298	-290	-284	-275	-215
Additional Paid-In Capital	16.8%	556	476	450	446	444	441	439	437	381	375	371	370	347	346	250
Shares Outstanding	11.2%	76.00	69.00	65.00	65.00	65.00	65.00	64.00	57.00	52.00	52.00	52.00	51.00	-	-	-
Float	-	-	-	-	369	-	-	-	205	-	-	-	62.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-55.6%	-24,866	-15,982	-11,561	-5,564	-8,457	-4,603	-5,774	-8,429	-9,782	-7,559	-5,831	-8,259	-12,386	-14,088	-12,509	-13,109	-14,438	-
Share Based Compensation	77.3%	4,524	2,551	2,487	2,499	2,552	1,818	1,648	1,647	4,185	3,824	1,224	953	745	1,006	1,081	988	879	-
Cashflow From Investing	-202.9%	-624	-206	-10,475	-243	-364	-491	-94.00	-2.00	-	-20.00	-	-35.00	-52.00	961	-122	-408	-182	-
Cashflow From Financing	321.6%	99,669	23,642	10,065	-409	9,950	57.00	348	54,477	10,082	1,019	1,995	22,547	759	-1,107	68,596	-3,023	-1,048	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LQDA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
Revenue	$ 2,972	$ 4,493
Costs and expenses:
Cost of revenue	1,467	654
Research and development	10,057	5,278
General and administrative	20,249	7,793
Total costs and expenses	31,773	13,725
Loss from operations	(28,801)	(9,232)
Other income (expense):
Interest income	1,880	922
Interest expense	(2,524)	(1,124)
Loss on extinguishment of debt	(11,483)	(2,311)
Total other expense, net	(12,127)	(2,513)
Net loss and comprehensive loss	$ (40,928)	$ (11,745)
Net loss per common share, basic (in dollars per share)	$ (0.54)	$ (0.18)
Net loss per common share, diluted (in dollars per share)	$ (0.54)	$ (0.18)
Weighted average common shares outstanding, basic (in shares)	75,393,907	64,656,424
Weighted average common shares outstanding, diluted (in shares)	75,393,907	64,656,424

LQDA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 157,858	$ 83,679
Accounts receivable, net	2,570	4,061
Inventory	3,517	0
Prepaid expenses and other current assets	3,991	2,159
Total current assets	167,936	89,899
Property, plant and equipment, net	5,576	4,480
Operating lease right-of-use assets, net	1,591	1,704
Indemnification asset, related party	6,712	6,707
Contract acquisition costs, net	7,798	7,922
Intangible asset, net	3,376	3,430
Goodwill	3,903	3,903
Other assets	224	287
Total assets	197,116	118,332
Current liabilities:
Accounts payable	2,490	1,396
Accrued expenses and other current liabilities	14,068	13,400
Revenue interest financing payable, current	4,153	2,615
Operating and finance lease liabilities, current	1,214	1,139
Total current liabilities	21,925	18,550
Litigation finance payable	6,710	6,707
Revenue interest financing payable, noncurrent	80,205	43,418
Operating and finance lease liabilities, noncurrent	2,016	2,364
Total liabilities	110,856	71,039
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock - 10,000,000 shares authorized, none outstanding	0	0
Common stock - $0.001 par value, 100,000,000 shares authorized as of March 31, 2024 and December 31, 2023 76,287,415 and 68,629,575 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	76	69
Additional paid-in capital	556,210	476,322
Accumulated deficit	(470,026)	(429,098)
Total stockholders' equity	86,260	47,293
Total liabilities and stockholders' equity	$ 197,116	$ 118,332

About Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

CEO	Dr. Roger A. Jeffs Ph.D.
WEBSITE	liquidia.com
INDUSTRY	Biotechnology
EMPLOYEES	63

Liquidia Corporation Frequently Asked Questions

What is the ticker symbol for Liquidia Corporation? What does LQDA stand for in stocks?

LQDA is the stock ticker symbol of Liquidia Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Liquidia Corporation (LQDA)?

As of Fri May 17 2024, market cap of Liquidia Corporation is 969.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LQDA stock?

You can check LQDA's fair value in chart for subscribers.

What is the fair value of LQDA stock?

You can check LQDA's fair value in chart for subscribers. The fair value of Liquidia Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Liquidia Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LQDA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Liquidia Corporation a good stock to buy?

The fair value guage provides a quick view whether LQDA is over valued or under valued. Whether Liquidia Corporation is cheap or expensive depends on the assumptions which impact Liquidia Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LQDA.

What is Liquidia Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LQDA's PE ratio (Price to Earnings) is -9.01 and Price to Sales (PS) ratio is 60.71. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LQDA PE ratio will change depending on the future growth rate expectations of investors.